Quarterly report · Q3
9265.TEDINET S100T8KZ
Period2023-06-01 → 2024-02-29
Filed2024-04-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥45.4bn | 2023-06-01 → 2024-02-29 | Cons. | Net sales |
| Revenue | ¥58.2bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥41.7bn | 2022-06-01 → 2023-02-28 | Cons. | Net sales |
| Operating income | ¥830m | 2023-06-01 → 2024-02-29 | Cons. | Operating income |
| Operating income | ¥895m | 2022-06-01 → 2023-02-28 | Cons. | Operating income |
| Ordinary income | ¥871m | 2023-06-01 → 2024-02-29 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥936m | 2022-06-01 → 2023-02-28 | Cons. | Ordinary income |
| Profit before tax | ¥721m | 2023-06-01 → 2024-02-29 | Cons. | Income before income taxes |
| Profit before tax | ¥333m | 2022-06-01 → 2023-02-28 | Cons. | Income before income taxes |
| Net income (owners) | ¥442m | 2023-06-01 → 2024-02-29 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥219m | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1m | 2022-06-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥438m | 2023-06-01 → 2024-02-29 | Cons. | Profit loss |
| Net income | −¥3m | 2022-06-01 → 2023-02-28 | Cons. | Profit loss |
| Total assets | ¥25.6bn | at 2024-02-29 | Cons. | Assets |
| Total assets | ¥24.6bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥22.5bn | at 2023-02-28 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥17.2bn | at 2024-02-29 | Cons. | Liabilities |
| Total liabilities | ¥16.6bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.4bn | at 2024-02-29 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.7bn | at 2023-02-28 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.5bn | at 2024-02-29 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.8bn | at 2023-05-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥173.23 | 2023-06-01 → 2024-02-29 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-14.83 | 2023-12-01 → 2024-02-29d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.83 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥0.46 | 2022-06-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥79.44 | 2022-12-01 → 2023-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.8% | at 2024-02-29 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.2% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2024-02-29 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2024-02-29 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2024-02-29 | −¥844m |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2023-06-01 → 2024-02-29 | ¥209m |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2023-06-01 → 2024-02-29 | ¥209m |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2023-06-01 → 2024-02-29 | ¥0 |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2023-06-01 → 2024-02-29 | ¥2m |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | revenue | 2023-06-01 → 2024-02-29 | ¥45.1bn |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2023-06-01 → 2024-02-29 | ¥45.1bn |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2023-06-01 → 2024-02-29 | ¥0 |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2023-06-01 → 2024-02-29 | ¥1.7bn |
| jpcrp040300-q3r_E33393-000Medical Mallreportable segment | revenue | 2023-06-01 → 2024-02-29 | ¥51m |
| jpcrp040300-q3r_E33393-000Medical Mallreportable segment | revenue external | 2023-06-01 → 2024-02-29 | ¥51m |
| jpcrp040300-q3r_E33393-000Medical Mallreportable segment | segment profit | 2023-06-01 → 2024-02-29 | ¥1m |
| —segment total | revenue | 2023-06-01 → 2024-02-29 | ¥45.4bn |
| —segment total | revenue external | 2023-06-01 → 2024-02-29 | ¥45.4bn |
| —segment total | revenue intersegment | 2023-06-01 → 2024-02-29 | ¥0 |
| —segment total | segment profit | 2023-06-01 → 2024-02-29 | ¥1.7bn |
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2023-02-28 | −¥11m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2023-02-28 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2023-02-28 | −¥690m |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥211m |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥211m |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2022-06-01 → 2023-02-28 | ¥0 |
| jpcrp040300-q3r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2022-06-01 → 2023-02-28 | ¥10m |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥41.5bn |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥41.5bn |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2022-06-01 → 2023-02-28 | ¥11m |
| jpcrp040300-q3r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2022-06-01 → 2023-02-28 | ¥1.6bn |
| jpcrp040300-q3r_E33393-000Medical Mallreportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥50m |
| jpcrp040300-q3r_E33393-000Medical Mallreportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥50m |
| jpcrp040300-q3r_E33393-000Medical Mallreportable segment | segment profit | 2022-06-01 → 2023-02-28 | ¥0 |
| —segment total | revenue | 2022-06-01 → 2023-02-28 | ¥41.7bn |
| —segment total | revenue external | 2022-06-01 → 2023-02-28 | ¥41.7bn |
| —segment total | revenue intersegment | 2022-06-01 → 2023-02-28 | ¥11m |
| —segment total | segment profit | 2022-06-01 → 2023-02-28 | ¥1.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 366
| Item | Context | Value | Unit |
|---|---|---|---|
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding receipts from contingent consideration (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding provision of allowance for doubtful accounts (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding impairment loss (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |